The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Vascular Biology

Background:

• Endothelial dysfunction is a key factor in the elevated cardiovascular risk observed in patients with chronic kidney disease (CKD).
• The soluble VEGF receptor 1 (sFlt-1), an antagonist of vascular endothelial growth factor (VEGF), is investigated for its potential role in CKD-associated endothelial dysfunction and impaired angiogenesis.

Purpose of the Study:

• To investigate the association between plasma sFlt-1 levels and endothelial dysfunction in patients with CKD.
• To explore the functional impact of sFlt-1 on angiogenesis, endothelial cell apoptosis, and nitric oxide generation in the context of CKD.

Main Methods:

• Plasma sFlt-1 levels were measured in 130 CKD patients (stages 3-5) and 56 controls.
• Multivariate regression analysis identified associations between sFlt-1, renal function, and von Willebrand factor (vWF).
• In vitro and in vivo assays (CAM assay, endothelial cell cultures, rat model) assessed the functional effects of sFlt-1 and its inhibition.

Main Results:

• CKD patients exhibited significantly higher plasma sFlt-1 levels compared to controls.
• sFlt-1 levels were independently associated with renal function and vWF levels.
• Both recombinant sFlt-1 and CKD patient serum demonstrated antiangiogenic properties, induced endothelial cell apoptosis, and reduced nitric oxide generation, effects reversed by anti-sFlt-1 antibody.

Conclusions:

• Excessive sFlt-1 is associated with endothelial dysfunction and impaired angiogenesis in CKD.
• Monocytes are identified as a potential source of increased sFlt-1 in CKD patients.
• Elevated sFlt-1 may serve as a predictive marker for cardiovascular risk in the CKD population.